Safety evaluation and probiotic effect of Lactobacillus brevis SLlac-18 on hyperuricemic mice

  • LI Jie ,
  • LI Yanjie ,
  • SHI Yan ,
  • LUO Jincheng ,
  • ZHOU Jian ,
  • SUN Xuewei ,
  • WANG Xue ,
  • SONG Lixin
Expand
  • 1(School of Public Health, Jiamusi University, Jiamusi 154003, China)
    2(Laboratory Animal Center, Jiamusi University, Jiamusi 154003, China)
    3(Baotou Disease Prevention Control Center, Baotou 014030, China)

Received date: 2024-11-13

  Revised date: 2025-04-30

  Online published: 2026-01-22

Abstract

Hyperuricaemia is a metabolic disease characterized by uric acid metabolism disorder.Probiotics have the characteristics of being economical and effective with few toxic side effects and relatively high safety for alleviating hyperuricemia.In this study, we evaluated the safety of a previously isolated strain of Lactobacillus brevis SLlac-18 from a pickle with potential uric acid-lowering function and constructed a hyperuricemia mice model to investigate the probiotic effects of L.brevis SLlac-18 on hyperuricemic mice.The results showed that L.brevis SLlac-18 had no haemolytic activity, and there were no significant differences in body weight, organ indices, and blood routine indexes in mice gavaged with strain compared to the control group, and no significant pathological changes in liver and kidney tissue were observed.Additionally, compared with the model group, the expression levels of uric acid and xanthine oxidase (XOD) in serum were decreased to 32.02% and 80.77% respectively in the SLlac-18 group (P<0.01), liver and kidney tissue damage was improved by L.brevis SLlac-18, and the XOD activity was decreased to 63.38% (P<0.01), the expression of uric acid reabsorption transporter protein GLUT9 was reduced to 23.74% and the expression the uric acid secretion transporter protein NPT1 was increased to 23.68%.In conclusion, L.brevis SLlac-18 exhibits a favorable safety profile and exerts beneficial effects in hyperuricemic mice through multiple pathways, holding promise for the prevention and adjuvant therapy of hyperuricemia.

Cite this article

LI Jie , LI Yanjie , SHI Yan , LUO Jincheng , ZHOU Jian , SUN Xuewei , WANG Xue , SONG Lixin . Safety evaluation and probiotic effect of Lactobacillus brevis SLlac-18 on hyperuricemic mice[J]. Food and Fermentation Industries, 2026 , 52(1) : 39 -46 . DOI: 10.13995/j.cnki.11-1802/ts.041587

References

[1] JUNG S W, KIM S M, KIM Y G, et al.Uric acid and inflammation in kidney disease[J].American Journal of Physiology.Renal Physiology, 2020, 318(6):F1327-F1340.
[2] 陈柔柔, 刘煜.高尿酸血症及痛风与肠道菌群相关性的研究进展[J].南京医科大学学报(自然科学版), 2020, 40(10):1560-1564.
CHEN R R, LIU Y.Research update on the association of gut microbiota with hyperuricemia and gout[J].Journal of Nanjing Medical University (Natural Sciences), 2020, 40(10):1560-1564.
[3] WANG J, CHEN Y, ZHONG H, et al.The gut microbiota as a target to control hyperuricemia pathogenesis:Potential mechanisms and therapeutic strategies[J].Critical Reviews in Food Science and Nutrition, 2022, 62(14):3979-3989.
[4] PASCART T, RICHETTE P.Investigational drugs for hyperuricemia, an update on recent developments[J].Expert Opinion on Investigational Drugs, 2018, 27(5):437-444.
[5] CHIEN C Y, CHIEN Y J, LIN Y H, et al.Supplementation of Lactobacillus plantarum (TCI227) prevented potassium-oxonate-induced hyperuricemia in rats[J].Nutrients, 2022, 14(22):4832.
[6] CAO J Y, WANG T, LIU Y S, et al.Lactobacillus fermentum F40-4 ameliorates hyperuricemia by modulating the gut microbiota and alleviating inflammation in mice[J].Food & Function, 2023, 14(7):3259-3268.
[7] HAMADA T, HISATOME I, WAKIMIZU T, et al.Lactobacillus gasseri PA-3 reduces serum uric acid levels in patients with marginal hyperuricemia[J].Nucleosides, Nucleotides & Nucleic Acids, 2022, 41(4):361-369.
[8] LEE Y J, KIM N, WERLINGER P, et al.Probiotic characterization of Lactobacillus brevis MJM60390 and in vivo assessment of its antihyperuricemic activity[J].Journal of Medicinal Food, 2022, 25(4):367-380.
[9] WANG H N, MEI L, DENG Y, et al.Lactobacillus brevis DM9218 ameliorates fructose-induced hyperuricemia through inosine degradation and manipulation of intestinal dysbiosis[J].Nutrition, 2019, 62:63-73.
[10] CANNON J P, LEE T A, BOLANOS J T, et al.Pathogenic relevance of Lactobacillus:A retrospective review of over 200 cases[J].European Journal of Clinical Microbiology and Infectious Diseases, 2005, 24(1):31-40.
[11] KOTHARI D, PATEL S, KIM S K.Probiotic supplements might not be universally-effective and safe:A review[J].Biomedicine & Pharmacotherapy, 2019, 111:537-547.
[12] 李杰, 张鹏霞, 周健, 等.传统泡菜中高效降解核苷乳酸菌的筛选及其特性研究[J].食品与发酵工业, 2024, 50(12):227-233.
LI J, ZHANG P X, ZHOU J, et al.Isolation of efficient nucleoside-degrading lactic acid bacteria from traditional pickles and their probiotic properties[J].Food and Fermentation Industries, 2024, 50(12):227-233.
[13] 贾盛, 候萌, 陈伟丽, 等.一株羊源巨大芽孢杆菌BM24的分离鉴定及安全性评价[J].动物营养学报, 2024, 36(9):6083-6094.
JIA S, HOU M, CHEN W L, et al.Isolation, identification and safety evaluation of a sheep-derived Bacillus megaterium BM24[J].Chinese Journal of Animal Nutrition, 2024, 36(9):6083-6094.
[14] BINDA S, HILL C, JOHANSEN E, et al.Criteria to qualify microorganisms as “probiotic” in foods and dietary supplements[J].Frontiers in Microbiology, 2020, 11:1662.
[15] 冯媛媛, 乔琳, 姚宏明, 等.益生菌安全性和有效性评价方法的研究进展[J].中国畜牧兽医, 2017, 44(7):2022-2032.
FENG Y Y, QIAO L, YAO H M, et al.Research progress on the evaluation methods of safety and efficacy of probiotics[J].China Animal Husbandry & Veterinary Medicine, 2017, 44(7):2022-2032.
[16] MAIUOLO J, OPPEDISANO F, GRATTERI S, et al.Regulation of uric acid metabolism and excretion[J].International Journal of Cardiology, 2016, 213:8-14.
[17] 杨新如, 唐甲越, 曾小群, 等.益生菌缓解高尿酸血症:研究现状、作用机制及面临的挑战[J].食品工业科技, 2024, 45(20):415-425.
YANG X R, TANG J Y, ZENG X Q, et al.Probiotics in alleviating hyperuricemia:Research status, mechanism of action and challenges[J].Science and Technology of Food Industry, 2024, 45(20):415-425.
[18] NI C X, LI X, WANG L L, et al.Lactic acid bacteria strains relieve hyperuricaemia by suppressing xanthine oxidase activity via a short-chain fatty acid-dependent mechanism[J].Food & Function, 2021, 12(15):7054-7067.
[19] ZHOU Y, ZHAO M C, PU Z Y, et al.Relationship between oxidative stress and inflammation in hyperuricemia:Analysis based on asymptomatic young patients with primary hyperuricemia[J].Medicine, 2018, 97(49):e13108.
[20] XU D X, LYU Q L, WANG X F, et al.Hyperuricemia is associated with impaired intestinal permeability in mice[J].American Journal of Physiology.Gastrointestinal and Liver Physiology, 2019, 317(4):G484-G492.
[21] SHI R J, YE J, FAN H, et al.Lactobacillus plantarum LLY-606 supplementation ameliorates hyperuricemia via modulating intestinal homeostasis and relieving inflammation[J].Food & Function, 2023, 14(12):5663-5677.
[22] WANG Q X, LIANG J R, ZOU Q H, et al. Tryptophan metabolism-regulating probiotics alleviate hyperuricemia by protecting the gut barrier integrity and enhancing colonic uric acid excretion[J]. Journal of Agricultural and Food Chemistry, 2024, 72(48):26746-26761.
[23] 辛家东, 周嘉宝, 吴志远, 等.尿酸排泄及其相关转运蛋白在高尿酸血症中的研究进展[J].中国全科医学, 2023, 26(15):1916-1922.
XIN J D, ZHOU J B, WU Z Y, et al.Advances in urate excretion and urate transporters in hyperuricemia[J].Chinese General Practice, 2023, 26(15):1916-1922.
[24] FU Y, LUO X D, LI J Z, et al. Host-derived Lactobacillus plantarum alleviates hyperuricemia by improving gut microbial community and hydrolase-mediated degradation of purine nucleosides[J]. eLife, 2024, 13: e100068.
[25] 张书灵, 唐鑫, 毛丙永, 等.格氏乳杆菌CCFM1346通过调节尿酸代谢和改善肾脏炎症缓解小鼠的高尿酸血症[J].食品与发酵工业, 2025, 51(3):52-57.
ZHANG S L, TANG X, MAO B Y, et al.Lactobacillus gasseri CCFM1346 alleviates hyperuricemia in mice by regulating uric acid metabolism and improving kidney inflammation[J].Food and Fermentation Industries, 2025, 51(3):52-57.
Outlines

/

〈 〉